Results 31 to 40 of about 7,739 (166)
The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease [PDF]
, 2014 Objective To evaluate the effect of heart rate reduction by ivabradine on coronary collateral function in patients with chronic stable coronary artery disease (CAD). Methods This was a prospective randomised placebo-controlled monocentre trial in a
Schild, Deborah +7 more
core +1 more source
Frontiers in Pediatrics, 2020 We report on a 12-month-old girl with an ectopic atrial tachycardia successfully treated with the combination of a beta blocking agent and Ivabradine that acts on cardiac pacemaker cells by selectively inhibiting the If channel.
Holger Michel +4 more
doaj +1 more source
Ivabradine Prevents Low Shear Stress Induced Endothelial Inflammation and Oxidative Stress via mTOR/eNOS Pathway. [PDF]
PLoS ONE, 2016 Ivabradine not only reduces heart rate but has other cardiac and vascular protective effects including anti-inflammation and anti-oxidation. Since endothelial nitric oxide synthase (eNOS) is a crucial enzyme in maintaining endothelial activity, we aimed ...
Bing Li +3 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundSympathetic and parasympathetic influences on heart rate (HR), which are governed by baroreflex mechanisms, are integrated at the cardiac sinus node through hyperpolarization‐activated cyclic nucleotide–gated channels (HCN4).
Karsten Heusser +11 more
doaj +1 more source
Identification of the molecular site of ivabradine binding to HCN4 channels.
PLoS ONE, 2013 Ivabradine is a specific heart rate-reducing agent approved as a treatment of chronic stable angina. Its mode of action involves a selective and specific block of HCN channels, the molecular components of sinoatrial "funny" (f)-channels.
Annalisa Bucchi +6 more
doaj +1 more source
The role of ivabradine and beta blockers in the treatment of cardiovascular diseases
, 2021 The thesis is on the development and history of ivabradine and its uses on cardiovascular diseases. It also compared it against beta blockers and how they work and interact on certain diseases.
Mungur, Asad Fawzi
core
PROTECTIVE EFFECTS OF IVABRADINE (ALONE AND COMBINED WITH ATENOLOL OR ENALAPRIL) ON EXPERIMENTALLY-INDUCED ACUTE MYOCARDIAL INFARCTION IN ALBINO RATS [PDF]
Zagazig University Medical Journal, 2017 ackground: Cardiovascular disease (CVD) is the leading cause of death worldwide. Deaths are mostly attributable to coronary artery disease (CAD). Ivabradine, a pure heart rate lowering agent, acts by inhibiting the pacemaker If current in the sinoatrial ...
Shireen Mahmoud +3 more
doaj +1 more source
, 2011 The importance of heart rate in human health and disease has been well known to clinicians for quite some time. Recent epidemiologic studies have further strengthened this concept.
Balram Bhargava +3 more
core +1 more source
American Heart Journal Plus, 2022 Heart rate (HR) lowering during acute coronary syndrome (ACS) is beneficial as it reduces myocardial oxygen consumption. However, the role of ivabradine as an HR-lowering agent in the setting of ACS is not clear.
Josip A. Borovac +8 more
doaj +1 more source
Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction
ESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi +9 more
wiley +1 more source